(Q37139726)

18 August 2017

1 reference

title

Pharmaceutical management of ovarian cancer : current status (English)

1 reference

18 August 2017

1 reference

Maurie Markman

1

1 reference

18 August 2017

publication date

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

68

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

771-789

1 reference

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

18 August 2017

cites work

1 reference

12 December 2020

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

1 reference

12 December 2020

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

12 December 2020

A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma

1 reference

12 December 2020

Hexamethylmelamine as a Single Second-Line Agent in Ovarian Cancer: Follow-up Report and Review of the Literature

1 reference

12 December 2020

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

12 December 2020

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

12 December 2020

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

12 December 2020

Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up

1 reference

12 December 2020

Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.

1 reference

12 December 2020

Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer

1 reference

12 December 2020

Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines

1 reference

12 December 2020

Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials

1 reference

12 December 2020

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease

1 reference

12 December 2020

Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer

1 reference

12 December 2020

Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer

1 reference

12 December 2020

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

12 December 2020

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer

1 reference

12 December 2020

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program

1 reference

12 December 2020

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

12 December 2020

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

12 December 2020

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

12 December 2020

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

12 December 2020

Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital

1 reference

12 December 2020

A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer

1 reference

12 December 2020

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

1 reference

12 December 2020

Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica

1 reference

12 December 2020

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

12 December 2020

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

1 reference

12 December 2020

PROGESTOGEN THERAPY FOR OVARIAN CARCINOMA

1 reference

12 December 2020

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

12 December 2020

Phase I trial of taxol given as a 3-hour infusion every 21 days

1 reference

12 December 2020

Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study

1 reference

12 December 2020

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

1 reference

12 December 2020

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

1 reference

12 December 2020

High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group

1 reference

12 December 2020

Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer

1 reference

12 December 2020

Chemotherapy for advanced or recurrent gynecologic cancer

1 reference

12 December 2020

Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses

1 reference

12 December 2020

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

1 reference

12 December 2020

Carcinoma of the ovary. A clinicopathological study of 86 autopsied cases with special reference to mode of spread

1 reference

12 December 2020

A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer

1 reference

12 December 2020

Toxic effects of cis-dichlorodiammineplatinum(II) in man.

1 reference

12 December 2020

Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

1 reference

12 December 2020

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

12 December 2020

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

12 December 2020

Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors

1 reference

12 December 2020

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

1 reference

12 December 2020

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

1 reference

12 December 2020

Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer

1 reference

12 December 2020

Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions

1 reference

12 December 2020

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

1 reference

12 December 2020

The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro

1 reference

12 December 2020

Drugs five years later. Cisplatin

1 reference

12 December 2020

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

12 December 2020

Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions

1 reference

12 December 2020

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

1 reference

12 December 2020

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

12 December 2020

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

1 reference

12 December 2020

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125

1 reference

12 December 2020

6-Dehydro-6,17 alpha-dimethylprogesterone (NSC-123018) for the treatment of metastatic and recurrent ovarian carcinoma.

1 reference

12 December 2020

A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: A comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals

1 reference

12 December 2020

Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism

1 reference

12 December 2020

A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

1 reference

12 December 2020

Measurement of tumor cell activity in short-term primary culture. Clinical significance in women with ovarian cancer

1 reference

12 December 2020

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

1 reference

12 December 2020

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial

1 reference

12 December 2020

Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital

1 reference

12 December 2020

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

1 reference

12 December 2020

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

1 reference

12 December 2020

Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer

1 reference

12 December 2020

Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study

1 reference

12 December 2020

Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

1 reference

12 December 2020

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse

1 reference

12 December 2020

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

1 reference

12 December 2020

Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?

1 reference

12 December 2020

Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care

1 reference

12 December 2020

Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment

1 reference

12 December 2020

Second malignant neoplasms among long-term survivors of ovarian cancer

1 reference

12 December 2020

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

1 reference

12 December 2020

Risk of leukemia after platinum-based chemotherapy for ovarian cancer

1 reference

12 December 2020

Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.

1 reference

12 December 2020

A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.

1 reference

12 December 2020

Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.

1 reference

12 December 2020

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

1 reference

12 December 2020

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Use of nitrogen mustard in treatment of serous effusions of neoplastic origin

1 reference

12 December 2020

CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.

1 reference

12 December 2020

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

12 December 2020

A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy

1 reference

12 December 2020

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial

1 reference

12 December 2020

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

1 reference

12 December 2020

A critique of surgical cytoreduction in advanced ovarian cancer.

1 reference

12 December 2020

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study

1 reference

12 December 2020

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

1 reference

12 December 2020

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

1 reference

12 December 2020

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays

1 reference

12 December 2020

Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

1 reference

12 December 2020

Theoretical and experimental bases of intraperitoneal chemotherapy.

1 reference

12 December 2020

The impact of received dose intensity on the outcome of advanced ovarian cancer

1 reference

12 December 2020

Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study

1 reference

12 December 2020

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

12 December 2020

Intraperitoneal antineoplastic drug delivery: rationale and results

1 reference

12 December 2020

A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer

1 reference

12 December 2020

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

12 December 2020

Systematic review of adjuvant care for women with Stage I ovarian carcinoma.

1 reference

12 December 2020

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

12 December 2020

Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

1 reference

12 December 2020

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

1 reference

12 December 2020

A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer

1 reference

12 December 2020

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

1 reference

12 December 2020

Epithelial carcinoma of the ovary: current strategies

1 reference

12 December 2020

A case of chronic paclitaxel administration in ovarian cancer

1 reference

12 December 2020

Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Hormone therapy in epithelial ovarian cancer

1 reference

12 December 2020

International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer

1 reference

12 December 2020

Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer

1 reference

12 December 2020

In vitro assay-assisted treatment selection for women with breast or ovarian cancer

1 reference

12 December 2020

1 reference

12 December 2020

Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials

1 reference

12 December 2020

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

1 reference

12 December 2020

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

12 December 2020

A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study

1 reference

12 December 2020

Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group

1 reference

12 December 2020

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

1 reference

12 December 2020

Second-line treatment of ovarian cancer

1 reference

12 December 2020

Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials

1 reference

12 December 2020

Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer

1 reference

12 December 2020

Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy

1 reference

12 December 2020

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

12 December 2020

A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.

1 reference

12 December 2020

Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. GICOG (Gruppo Interregionale Cooperativo Oncologico Ginecologia), Italy

1 reference

12 December 2020

Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma

1 reference

12 December 2020

Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens

1 reference

12 December 2020

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity

1 reference

12 December 2020

Impact of doxorubicin on survival in advanced ovarian cancer

1 reference

12 December 2020

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer

1 reference

12 December 2020

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

12 December 2020

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies

1 reference

12 December 2020

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial

1 reference

12 December 2020

Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.

1 reference

12 December 2020

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

1 reference

12 December 2020

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

1 reference

12 December 2020

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

1 reference

12 December 2020

Intraperitoneal chemotherapy

1 reference

12 December 2020

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study

1 reference

12 December 2020

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

1 reference

12 December 2020

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

1 reference

12 December 2020

Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum

1 reference

12 December 2020

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy

1 reference

12 December 2020

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival

1 reference

12 December 2020

Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer

1 reference

12 December 2020

Death from anaphylaxis to cisplatin: a case report

1 reference

12 December 2020

Chemotherapeutic management of advanced ovarian carcinoma

1 reference

12 December 2020

Viewing ovarian cancer as a "chronic disease": what exactly does this mean?

1 reference

12 December 2020

Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience

1 reference

12 December 2020

Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

1 reference

12 December 2020

Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients

1 reference

12 December 2020

Cis-diamminedichloroplatinum (II). A new anticancer drug

1 reference

12 December 2020

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

12 December 2020

Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation

1 reference

12 December 2020

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

12 December 2020

Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity

1 reference

12 December 2020

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

1 reference

12 December 2020

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

12 December 2020

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study

1 reference

12 December 2020

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis

1 reference

12 December 2020

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

12 December 2020

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma

1 reference

12 December 2020

Chemotherapy sensitivity and resistance assays: a systematic review

1 reference

12 December 2020

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary

1 reference

12 December 2020

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

1 reference

12 December 2020

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

1 reference

12 December 2020

Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay

1 reference

12 December 2020

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

12 December 2020

Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT

1 reference

12 December 2020

Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients

1 reference

12 December 2020

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

12 December 2020

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

1 reference

12 December 2020

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

1 reference

12 December 2020

A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity

1 reference

12 December 2020

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

12 December 2020

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Clinical features of hypersensitivity reactions to carboplatin

1 reference

12 December 2020

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

12 December 2020

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

12 December 2020

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

12 December 2020

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

12 December 2020

Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer

1 reference

12 December 2020

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

12 December 2020

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

12 December 2020

The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer

1 reference

12 December 2020

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

12 December 2020

The myth of measurable disease in ovarian cancer.

1 reference

12 December 2020

Treatment of ovarian cancer with thiotepa.

1 reference

12 December 2020

Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis

1 reference

12 December 2020

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

12 December 2020

Optimizing primary chemotherapy in ovarian cancer

1 reference

12 December 2020

Chronic administration of single-agent paclitaxel in gynecologic malignancies

1 reference

12 December 2020

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

1 reference

12 December 2020

Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research.

1 reference

12 December 2020

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients

1 reference

12 December 2020

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

1 reference

12 December 2020

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

12 December 2020

Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer

1 reference

12 December 2020

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

12 December 2020

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

12 December 2020

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study

1 reference

12 December 2020

Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials

1 reference

12 December 2020

10.2165/00003495-200868060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

18 August 2017

1002089462

0 references

1 reference